AllSquare Wealth Management LLC Has $133,000 Position in Amgen Inc. (NASDAQ:AMGN)

AllSquare Wealth Management LLC reduced its position in Amgen Inc. (NASDAQ:AMGN) by 7.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 577 shares of the medical research company’s stock after selling 45 shares during the quarter. AllSquare Wealth Management LLC’s holdings in Amgen were worth $133,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the company. Security National Trust Co. boosted its position in Amgen by 0.4% in the fourth quarter. Security National Trust Co. now owns 10,089 shares of the medical research company’s stock worth $2,320,000 after purchasing an additional 40 shares during the last quarter. Aspiriant LLC boosted its stake in shares of Amgen by 2.1% during the 4th quarter. Aspiriant LLC now owns 2,055 shares of the medical research company’s stock worth $473,000 after acquiring an additional 42 shares during the last quarter. Shoker Investment Counsel Inc. grew its position in shares of Amgen by 0.4% during the 3rd quarter. Shoker Investment Counsel Inc. now owns 9,670 shares of the medical research company’s stock valued at $2,457,000 after acquiring an additional 43 shares during the period. Nachman Norwood & Parrott Inc raised its stake in Amgen by 0.5% during the 4th quarter. Nachman Norwood & Parrott Inc now owns 8,816 shares of the medical research company’s stock worth $2,027,000 after acquiring an additional 43 shares during the period. Finally, Smithfield Trust Co. grew its position in shares of Amgen by 1.1% during the third quarter. Smithfield Trust Co. now owns 4,033 shares of the medical research company’s stock worth $1,025,000 after purchasing an additional 44 shares in the last quarter. Institutional investors own 75.23% of the company’s stock.

Shares of NASDAQ AMGN traded up $1.29 during mid-day trading on Tuesday, hitting $232.76. The stock had a trading volume of 109,951 shares, compared to its average volume of 2,524,084. The firm has a market cap of $134.43 billion, a PE ratio of 18.67, a PEG ratio of 1.90 and a beta of 0.76. The company has a debt-to-equity ratio of 3.12, a quick ratio of 1.88 and a current ratio of 2.28. The company has a 50 day moving average of $240.38 and a two-hundred day moving average of $236.73. Amgen Inc. has a twelve month low of $177.05 and a twelve month high of $276.69.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Monday, February 1st. The medical research company reported $3.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.39 by $0.42. The company had revenue of $6.63 billion during the quarter, compared to analyst estimates of $6.57 billion. Amgen had a net margin of 29.42% and a return on equity of 95.55%. Amgen’s revenue for the quarter was up 7.1% compared to the same quarter last year. During the same period last year, the firm posted $3.64 EPS. Equities research analysts predict that Amgen Inc. will post 16.15 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 8th. Investors of record on Monday, February 15th will be given a dividend of $1.76 per share. The ex-dividend date is Thursday, February 11th. This is an increase from Amgen’s previous quarterly dividend of $1.60. This represents a $7.04 dividend on an annualized basis and a yield of 3.02%. Amgen’s payout ratio is currently 47.50%.

A number of brokerages recently issued reports on AMGN. BMO Capital Markets lowered their price target on Amgen from $308.00 to $304.00 and set an “outperform” rating for the company in a research report on Thursday, October 29th. The Goldman Sachs Group cut shares of Amgen from a “conviction-buy” rating to a “buy” rating in a research note on Tuesday, December 15th. Morgan Stanley reduced their price objective on shares of Amgen from $285.00 to $277.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 3rd. Barclays dropped their target price on Amgen from $250.00 to $242.00 and set an “equal weight” rating for the company in a research report on Thursday, October 29th. Finally, Credit Suisse Group reduced their price target on Amgen from $280.00 to $265.00 and set an “outperform” rating on the stock in a report on Wednesday, February 3rd. Eleven analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $255.39.

In related news, EVP Jonathan P. Graham sold 11,110 shares of Amgen stock in a transaction on Thursday, February 4th. The shares were sold at an average price of $236.51, for a total value of $2,627,626.10. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Ronald D. Sugar sold 1,000 shares of the business’s stock in a transaction on Wednesday, January 13th. The stock was sold at an average price of $235.99, for a total transaction of $235,990.00. Following the completion of the sale, the director now directly owns 16,805 shares of the company’s stock, valued at approximately $3,965,811.95. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,360 shares of company stock worth $3,161,514. 0.36% of the stock is owned by corporate insiders.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease.

Further Reading: Equity Income

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.